Genedx Holdings Corp. - Class A (WGS) closed at $55.12 on November 11, 2026, up 0.5% from the previous close, on volume of 874,925 shares (30-day average 924,614).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Put Spread | 13-Nov-2655 : 60 P | 16,006 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
GeneDx to Participate in Upcoming Investor Conferences
Business Wire (Wed, 11-Nov 4:05 PM ET)
Business Wire (Tue, 10-Nov 8:30 AM ET)
GeneDx Holdings (WGS) Receives a Buy from Piper Sandler
TipRanks (Tue, 10-Nov 8:06 AM ET)
Guggenheim Sticks to Its Buy Rating for GeneDx Holdings (WGS)
TipRanks (Tue, 10-Nov 7:28 AM ET)
Canaccord Genuity Reaffirms Their Buy Rating on GeneDx Holdings (WGS)
TipRanks (Tue, 10-Nov 7:28 AM ET)
GeneDx falls as Q4 outlook misses consensus
Seeking Alpha News (Tue, 10-Nov 7:08 AM ET)
GeneDx Holdings (WGS) Gets a Buy from BTIG
TipRanks (Tue, 10-Nov 6:16 AM ET)
GeneDx Holdings GAAP EPS of -$0.41 misses by $0.03, revenue of $123.1M beats by $0.18M
Seeking Alpha News (Mon, 9-Nov 4:28 PM ET)
GeneDx Reports Third Quarter 2026 Financial Results
Business Wire (Mon, 9-Nov 4:05 PM ET)
Cathie Wood's Ark Invest buys $96M of SpaceX, adds to Nvidia and AMD; trims Broadcom
Seeking Alpha News (Mon, 9-Nov 7:05 AM ET)
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
Genedx Holdings Corp. - Class A trades on the NASDAQ stock market under the symbol WGS.
As of November 11, 2026, WGS stock price climbed to $55.12 with 874,925 million shares trading.
WGS has a beta of 0.56, meaning it tends to be less sensitive to market movements. WGS has a correlation of 0.01 to the broad based SPY ETF.
WGS has a market cap of $1.65 billion. This is considered a Small Cap stock.
Last quarter Genedx Holdings Corp. - Class A reported $123 million in Revenue and $.28 earnings per share. This beat revenue expectation by $340,000 and exceeded earnings estimates by $.21.
In the last 3 years, WGS traded as high as $170.87 and as low as $1.16.
The top ETF exchange traded funds that WGS belongs to (by Net Assets): ARKK, ARKE, VTI, ARKG, IWM.
WGS has underperformed the market in the last year with a price return of -61.4% while the SPY ETF gained +12.6%. WGS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.2% and -12.1%, respectively, while the SPY returned -1.5% and -1.3%, respectively.
WGS support price is $51.67 and resistance is $57.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that WGS shares will trade within this expected range on the day.
